SCHEMBL1135210

SCHEMBL1135210

COc1cccc(Oc2ccc(C=O)c(B3OC(C)(C)C(C)(C)O3)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
TRIM24 O15164 1/20 0.41
TYR P14679 1/20 0.41
TRIM33 Q9UPN9 1/20 0.41
SNCA P37840 1/20 0.39
MTNR1B P49286 6/20 0.39
MTNR1A P48039 4/20 0.39
ERN1 O75460 2/20 0.38
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
POLB P06746 2/20 0.36
KDM4E B2RXH2 1/20 0.36
PGR P06401 3/20 0.36
LIPE Q05469 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1135193 0.91 ALDH1A1 (0.50) ALDH1A1TRIM24TYRTRIM33SNCA
SCHEMBL1135188 0.88 ERN1 (0.40) ALDH1A1ERN1LMNACYP1A2CYP2C9
SCHEMBL13127061 0.85 ACACB (0.39) ALDH1A1SMN1; SMN2ERN1CYP1A2CYP2C9
SCHEMBL1135179 0.84 ERN1 (0.42) ALDH1A1SMN1; SMN2ERN1POLBLIPE
SCHEMBL1135225 0.83 ALDH1A1 (0.42) ALDH1A1LMNACYP2C9CYP2C19KDM4E
SCHEMBL1135226 0.83 MAOB (0.46) ERN1POLB
SCHEMBL1135232 0.82 LMNA (0.44) ALDH1A1LMNALIPE
SCHEMBL1135167 0.82 LIPE (0.32) LIPE
SCHEMBL25594012 0.80 ERN1 (0.49) ALDH1A1TRIM24TYRTRIM33SNCA
SCHEMBL1135177 0.79 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2ERN1LMNACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2285384-A2 BORON-CONTAINING SMALL MOLECULES Anacor Pharmaceuticals, Inc. (US) 2011-02-23 EP disclosed
US-20100256092-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2010-10-07 US disclosed
US-20100256092-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2010-10-07 US disclosed
US-20100256092-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2010-10-07 US disclosed
WO-2009140309-A2 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2009-11-19 WO disclosed
WO-2009140309-A2 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256092-A1 BORON-CONTAINING SMALL MOLECULES BCL6B, BCL6, BTD ALDH1A1 4190/4885SMN1; SMN2 4069/4885TRIM24 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.